Waters Corporation (NYSE: WAT) today announced that the U.S. Food and Drug Administration (FDA) has cleared the Onclarity HPV ...

Waters Corporation WAT shares are up on Wednesday as the company announced FDA clearance for its Onclarity HPV ...

"Hearst Magazines and Yahoo may earn commission or revenue on some items through these links." Cervical cancer screening is about to get a lot more convenient. That’s because the latest cervical ...

The US FDA's approval of Waters' at-home cervical cancer screening kit marks a significant step in enhancing early detection and reducing fatalities. This move positively impacted Waters' stocks, ...

According to the World Health Organization (WHO), in 2022 cervical cancer was the fourth most common cancer among women worldwide, with about 660,000 new cases. Studies project that cervical cancer ...

The life sciences and diagnostics company said Wednesday the regulator cleared its Onclarity HPV Self-Collection Kit and approved the BD Onclarity HPV Assay with extended genotyping for at-home use.

Recent health sector developments include the US FDA's approval of Waters' cervical cancer screening kit, tightening ...

Add Yahoo as a preferred source to see more of our stories on Google. For decades, cervical cancer has been framed as a problem of youth—something caught early, something prevented young, something ...

Large multi-institution PROSPR II study finds big gaps in access, timely care in cervical, colorectal and lung cancers across U.S. Cancer screening is incredibly beneficial, but only when it’s done ...

States are eliminating out-of-pocket costs for follow-up cancer tests, aiming to reduce delays, improve early detection, and address racial and income-based disparities in care.

Add Yahoo as a preferred source to see more of our stories on Google. Cervical cancer screening is about to get a lot more convenient. That’s because the latest cervical cancer screening guidelines ...

FDA-approved BD Onclarity HPV Assay is the most comprehensive screening tool for HPV in the U.S.1,4 with extended genotyping and end-to-end automated lab workflows. At-home self-collection ...